Lenacapavir Rollout Runs Into the Arithmetic of Supply

Six hundred thousand doses. That is the quantity of twice-yearly injectable pre-exposure prophylaxis available worldwide this year, and the Global Fund together with the United States government has reserved all of it, splitting the volume roughly in half. The figure explains why the most closely watched session on the opening morning of the 26th International AIDS Conference in Rio de Janeiro was not about whether the drug works.

That session, held on Monday from 09:30 in Room 204 and convened jointly by the Gates Foundation, Unitaid and the World Health Organization, was titled "From evidence to access: implementation science to inform lenacapavir scale-up". Its subject was logistics, not pharmacology. Six hours later the WHO used its own satellite to set out updated recommendations covering long-acting HIV treatment, pre-exposure prophylaxis, doxycycline post-exposure prophylaxis and national surveillance systems, according to the agency's published conference programme.

Supply measured in rationed doses

The lenacapavir rollout has moved unusually fast by the standards of global health procurement. WHO recommended the twice-yearly injection as an additional prevention option in July 2025, at the International AIDS Society meeting in Kigali. Initial shipments reached sub-Saharan Africa by the end of that year, and the first national programmes, Kenya among them, began administering doses in 2026.

Gilead Sciences said in April that PEPFAR and the Global Fund had made an additional investment enabling the manufacturer to reach one million more people, lifting the combined commitment to three million through 2028. The company said it supplies the product to both purchasers at no profit. Chief Executive Daniel O'Day called the medicine "one of the most important breakthroughs ever seen in HIV prevention" in the company's statement.

Volume, however, remains the binding limitation until generic manufacturing arrives. Gilead has signed six voluntary licensing agreements, with large-scale generic supply expected from 2027. Health Policy Watch has reported that those agreements cover roughly 120 mainly low-income and lower-middle-income countries, and that the parties involved anticipate reaching two million people within three years. Ambassador John Nkengasong, then leading PEPFAR, described the medicine as "a potentially tremendous opportunity to transform the impact of HIV programs" in comments the outlet carried.

Efficacy has stopped being the binding constraint

The clinical file continues to strengthen. Gilead said on 21 July that it would present long-term follow-up from the open-label extension phases of its two pivotal prevention trials. PURPOSE 1, conducted among women in sub-Saharan Africa, recorded no new infections across more than 7,178 person-years of follow-up. PURPOSE 2, which enrolled men and gender-diverse participants, accumulated 5,295 person-years and documented a single infection among participants who continued on the injection, and none among those who switched from daily oral prophylaxis.

Persistence, the metric that has historically undone daily pills, held up. Ninety-six per cent of PURPOSE 1 participants and 92 per cent of those in PURPOSE 2 stayed on the twice-yearly schedule through 52 weeks. Jared Baeten, a senior vice president at the company, tied the results to "scientific innovation and enduring partnerships" with affected communities in Gilead's announcement.

The company is also presenting Phase 3 results from ISLEND-1 and ISLEND-2, which pair islatravir with lenacapavir in a once-weekly oral treatment regimen, alongside five-year paediatric data on Biktarvy and two-year real-world outcomes from its BICSTaR programme. Taken together, the portfolio points toward a treatment and prevention model built around dosing intervals measured in weeks and months rather than days. That model reduces the number of clinic contacts a programme must sustain, which matters more in 2026 than it would have in 2023.

Price ladder running through 2027

Three prices now define the market, and the distance between them is the substance of the access debate. The branded product carries a United States list price of about $28,218 a year, the figure Gilead published when the prevention indication was approved. PEPFAR negotiated supply at roughly $60 per person per year for programme use beginning in 2026. The Gates Foundation, working with Unitaid and the Clinton Health Access Initiative, has arranged generic supply at about $40 per person per year from 2027, with analysts cited by Medscape suggesting production costs could fall toward $25 at sufficient volume.

A price of $40 changes the calculation that has governed HIV prevention budgeting for a decade. At that level the injection competes directly with the delivered cost of daily oral prophylaxis once adherence support, repeat testing and loss to follow-up are counted. The constraint shifts from the cost per dose to the cost of the system that administers it, and that is precisely where the damage of the past year has concentrated.

Delivery systems weakened at the wrong moment

UNAIDS data released in June showed that initiations of pre-exposure prophylaxis fell by 38 per cent across 62 countries between 2024 and 2025, while testing in high-burden settings declined by 22 per cent. Those two indicators are the entry points for any injectable prevention programme. A person cannot start lenacapavir without a negative HIV test, a clinical assessment and a scheduled return visit six months later.

The organisations that historically performed that work for populations at highest risk have contracted sharply. Al Jazeera, reporting an amfAR survey of 166 organisations across 46 countries, said more than 1,700 clinics had closed and over 16,000 workers had lost their jobs following delayed or cancelled awards. The result is a rare inversion in global health: a prevention technology arriving with secured financing and constrained delivery capacity, rather than the reverse.

This is why the framing of Monday's satellite session mattered. Implementation science, a discipline that occupies the unglamorous space between a licensed product and a functioning programme, has become the rate-limiting step. Questions under examination in Rio include which populations to prioritise while supply is rationed, whether injections can be delivered outside clinical settings, and how national regulators sequence approvals against procurement timetables.

Metrics that will matter in 2027

The lenacapavir rollout will be judged on a single number that nobody in Rio can yet supply: how many of the people who most need protection actually receive a second injection six months after the first. Coverage announcements, dose reservations and licensing agreements are inputs. Continuation is the output, and it depends on staffing, transport and community trust rather than on molecular design.

Against 1.2 million new infections recorded in 2025, three million people reached by 2028 would represent meaningful but partial coverage. The generic transition scheduled for 2027 is the moment when supply stops rationing the programme and delivery capacity becomes the sole constraint. On present evidence, that capacity is smaller than it was two years ago, which is the uncomfortable subtext running beneath a conference otherwise built around good news.